Human trials employing standardized extracts (e.g., SHR-5) at doses ranging from 200 to 680 mg/day have reported a low incidence of adverse events, primarily mild and transient symptoms such as dizziness, dry mouth, or gastrointestinal discomfort
Mechanistically, glutathione peroxidase 4 and ferrous iron, which are pivotal ferroptosis regulators, were upregulated in residual cells or tumors, and were hence potential therapeutic targets of persister cells
If the employer carved out anti-obesity drugs, that is a benefit exclusion not a medical-necessity denial and is not appealable through PA
Are you struggling to lose weight
This segment is expected to attract a growing share of prescriptions and patient interest as more oral formulations enter the market with proven efficacy